AstraZeneca Faces NPPA Heat Over Symbicort Pricing, Slapped Rs 60 Crore Showcause Notice
New Delhi: AstraZeneca Pharma India Limited has received a show cause notice from the National Pharmaceutical Pricing Authority (NPPA), which has raised a demand of Rs 60.49 crore plus interest over alleged overcharging on its asthma drug, Symbicort Turbuhaler. In a filing dated September 12, 2025, to BSE and NSE, the company stated, “Pursuant to […]